Core Viewpoint - The company acknowledges the need for continuous improvement by reflecting on its experiences and shortcomings [2] Company Response - The company responded to investor inquiries on September 1, indicating a commitment to recognize its deficiencies and make necessary improvements [2]

Group 1 - The company holds a 34% stake in Beijing Mengborun Biotechnology Co., Ltd. [1]

Core Viewpoint - The company, Shuanglu Pharmaceutical, confirmed its normal operational status and ongoing business activities, including recent acquisitions in the healthcare sector [1] Group 1: Company Operations - Shuanglu Pharmaceutical's main business activities include technology development, consulting, transfer, and hospital management [1] - The company has acquired Jinmei General Hospital (a tertiary hospital) and several secondary and primary hospitals, as well as community health service stations through its subsidiary, Shanxi Jinmei Guoke New Mile Medical Management Co., Ltd [1] - The company stated that it is currently in a normal operational phase, with all situations being normal [1]

Core Viewpoint - The company, Shuanglu Pharmaceutical, announced on September 1 that it will disclose changes in the number of shareholders in its regular reports, with a total of 58,492 shareholders as of June 30, 2025 [1] Summary by Category - Shareholder Information - As of June 30, 2025, the total number of shareholders for the company is reported to be 58,492 [1] - Reporting Practices - The company will provide updates on shareholder changes in its periodic reports [1]

Group 1 - The company, Shuanglu Pharmaceutical, is currently conducting supplementary research on its short-acting follicle-stimulating hormone (FSH) and plans to reapply for approval after the research is completed [1] - The long-acting recombinant human follicle-stimulating hormone (FSH-CTP) has already submitted its application for market approval [1]

Group 1 - The company, Shuanglu Pharmaceutical, stated on September 1 that Dapagliflozin is currently not listed on the network, and any updates will be communicated in a timely manner [2]

Group 1 - The company, Shuanglu Pharmaceutical, is committed to enhancing its e-commerce platform development [2]

Group 1 - The core viewpoint is that not all generic drugs are in highly competitive categories, and there are distinctions in quality among them [2] - The pharmaceutical market in China is expected to primarily focus on generic drugs due to its status as a developing country [2] - The company has been increasing its focus on innovative drugs and biopharmaceuticals for the past five years, with plans for new innovative product submissions in the future [2]

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问公司有布局溶瘤病毒产品的研发吗？研发进度情 况如何？ 双鹭药业（002038.SZ）9月1日在投资者互动平台表示，公司暂没有布局相关领域。 ...

Group 1 - The core issue raised by investors concerns the patent status of Dulaglutide and the delay in its submission for approval [2] - The company, Donglu Pharmaceutical, clarified on September 1 that there are no patent issues with its GLP-1 long-acting formulation and that it is currently preparing the necessary documentation for submission [2] - The specific timeline for the submission remains uncertain as the company is still in the process of gathering materials [2]